MK0354 Clinical Efficacy and Tolerability Study (0354-004)
NCT00337415
·
clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
65
Enrollment
INDUSTRY
Sponsor class
Conditions
Dyslipidemia
Interventions
DRUG:
MK0354
Sponsor
Merck Sharp & Dohme LLC